Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Completed 3Recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Myasthenia Gravis 6

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Interventional × zilucoplan × Clear all
NCT06435312 2026-05-08

ziMyG+

UCB Pharma

Phase 3 Enrolling by invitation
8 enrolled

Myasthenia Gravis

NCT04225871 2026-04-24

RAISE-XT

UCB Pharma

Phase 3 Active not recruiting
200 enrolled

Myasthenia Gravis

NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
31 enrolled 11 charts

Myasthenia Gravis

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Ohio State University

Phase 3 Recruiting
15 enrolled

Myasthenia Gravis

NCT05514873 2025-09-03

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

UCB Pharma

Phase 3 Completed
26 enrolled 14 charts

Myasthenia Gravis

NCT04115293 2025-07-16

RAISE

UCB Pharma

Phase 3 Completed
174 enrolled 19 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡